Adtalem Global Education Inc.

Adtalem Global Education Inc. is a Chicago-headquartered healthcare higher-education provider listed on the NYSE under ticker ATGE. Its brands include Chamberlain University, Walden University, and Caribbean medical and veterinary schools. The fact pack shows revenue of US$1.79 billion and net income of US$0.21 billion in 2025, up from US$1.05 billion and -US$0.085 billion in 2020. Market capitalization was US$3.87 billion and share price US$105.5 as of 2026-10.

Industry Position

Adtalem sits in Life & Services, specifically Healthcare Higher Education, Nursing & Medical Schools. The portfolio spans Chamberlain University and Walden University plus American University of the Caribbean School of Medicine, Ross University School of Medicine, and Ross University School of Veterinary Medicine. That mix covers nursing, medical, and veterinary education rather than one program line.

Revenue advanced from US$1.05 billion in 2020 to US$1.11 billion in 2021, US$1.38 billion in 2022, US$1.45 billion in 2023, US$1.58 billion in 2024, and US$1.79 billion in 2025. Net income was -US$0.085 billion, US$0.077 billion, US$0.3 billion, US$0.093 billion, US$0.138 billion, and US$0.21 billion across those years. The 2023 dip after 2022 shows earnings volatility despite revenue growth.

Competitive Advantages

The brand portfolio gives Adtalem multiple healthcare-education pathways: Chamberlain and Walden for university programs, AUC and RUSM for medicine, and RUSVM for veterinary medicine. The company employed 5,100 people and was founded in 1931. Its NYSE listing provides public-market access and a US$3.87 billion market capitalization as of 2025.

Financial resources expanded: assets were US$2.25 billion in 2020, US$2.3 billion in 2021, US$3.55 billion in 2022, US$3.35 billion in 2023, US$3.25 billion in 2024, and US$3.3 billion in 2025. Market capitalization rose from US$1.5 billion in 2020 to US$3.87 billion in 2025, while net income reached US$0.21 billion in 2025. The data show a larger public-market footprint alongside the named institutions.

Strategic Expansion

Expansion is visible in the revenue base, which moved from US$1.05 billion in 2020 to US$1.79 billion in 2025. The brand set includes Chamberlain, Walden, AUC, RUSM, and RUSVM. Asset growth from US$2.25 billion in 2020 to US$3.55 billion in 2022 indicates a larger operating and balance-sheet footprint.

The 2025 market capitalization of US$3.87 billion and US$105.5 share price as of 2026-10 reflect public-market scale. Assets stood at US$3.3 billion in 2025, below the 2022 peak of US$3.55 billion but above 2020. Revenue and net income both ended 2025 above 2020 levels.

Risks & Outlook

Earnings remain uneven: net income was -US$0.085 billion in 2020, US$0.3 billion in 2022, US$0.093 billion in 2023, and US$0.21 billion in 2025. The 2023 decline from 2022 shows that revenue growth has not translated into stable annual profit. Asset levels also fell from US$3.55 billion in 2022 to US$3.3 billion in 2025.

The company's focus on healthcare higher education, nursing, and medical schools creates exposure to the demand and operating conditions of those fields. Market capitalization of US$3.87 billion in 2025 compared with net income of US$0.21 billion sets a high valuation hurdle. The fact pack does not provide segment margins or enrollment data.

Outlook depends on sustaining the revenue progression from US$1.58 billion in 2024 to US$1.79 billion in 2025 while improving net income beyond US$0.21 billion. The brand portfolio and 5,100-person workforce provide a broad healthcare-education platform, but earnings volatility and the 2025 asset level of US$3.3 billion remain constraints. VerityRank Score of 71/100.